Insmed (NASDAQ: INSM) reported Q1 EPS of ($0.96), $0.01 worse than the analyst estimate of ($0.95). Revenue for the quarter came in at $21.9 million versus the consensus estimate of $19.62 million.

The Company now expects full-year 2019 revenues for ARIKAYCE to be in the range of $90 million to $105 million.

For earnings history and earnings-related data on Insmed (INSM) click here.